Domov › Akutna mieločna levkemija › Massachusetts › Boston
Klinične študije za Akutna mieločna levkemija v Boston, MA
44 študij za Akutna mieločna levkemija išče udeležence na lokacijah v Boston in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Vključevanje udeležencevFaza 1
- Dana-Farber Cancer Institute, Boston
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Vključevanje udeležencevFaza 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Vključevanje udeležencevFaza 3
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Vključevanje udeležencevFaza 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Vključevanje udeležencevFaza 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Vključevanje udeležencevFaza 2
- Tufts Medical Center, Boston
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Vključevanje udeležencevFaza 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Vključevanje udeležencevFaza 1/2
- Dana-Farber Cancer Center, Boston
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Vključevanje udeležencevFaza 3
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Vključevanje udeležencevFaza 2
- Dana-Farber Cancer Institute, Boston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Vključevanje udeležencevFaza 1/2
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Vključevanje udeležencevFaza 1/2
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
Vključevanje udeležencevFaza 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Vključevanje udeležencevFaza 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Vključevanje udeležencevFaza 1
- Dana-Farber Cancer Institute, Boston
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Vključevanje udeležencevFaza 1
- Dana-Farber Cancer Institute, Boston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Vključevanje udeležencevFaza 1/2
- Dana-Farber Cancer Institute, Boston
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Vključevanje udeležencevFaza 3
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Vključevanje udeležencevFaza 1
- Beth Israel Deaconess Medical Center, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Vključevanje udeležencevFaza 1Vabljeni zdravi prostovoljci
- Brigham and Women's Hospital, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Vključevanje udeležencevOpazovalna študija
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Ivosidenib as Post-HSCT Maintenance for AML
Vključevanje udeležencevFaza 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Vključevanje udeležencevFaza 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Vključevanje udeležencevFaza 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Vključevanje udeležencevFaza 1
- Dana Farber Cancer Institute, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Vključevanje udeležencevOpazovalna študija
- Dana-Farber Cancer Institute, Boston
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Vključevanje udeležencevFaza 1
- Beth Israel Deaconess Medical Center, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Vključevanje udeležencevFaza 1
- Dana Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Vključevanje udeležencevFaza 2/3
- Dana-Farber Cancer Institute, Boston
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Vključevanje udeležencevFaza 2
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
Vključevanje udeležencevFaza 1
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Vključevanje udeležencevFaza 1/2
- Massachusetts General Hospital, Boston
Ziftomenib Maintenance Post Allo-HCT
Vključevanje udeležencevFaza 1
- Massachusetts General Hospital, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Vključevanje udeležencevFaza 2
- Dana-Farber Cancer Institute, Boston
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Vključevanje udeležencevFaza 1
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Vključevanje udeležencevFaza 1
- Massachusetts General Hospital, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Vključevanje udeležencevFaza 2Vabljeni zdravi prostovoljci
- DFCI/BWH Brigham and Women's Hospital, Boston
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Vključevanje udeležencevFaza 1
- DFCI, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Vključevanje udeležencevFaza 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Novel Digital Application for Patients With Acute Leukemia
Vključevanje udeležencev
- Massachusetts General Hospital (MGH), Boston
IS-free Treg HaploHCT
Vključevanje udeležencevFaza 1
- Dana Farber Cancer Institute, Boston
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Vključevanje udeležencevVabljeni zdravi prostovoljci
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Vključevanje udeležencevFaza 1
- Dana Farber Cancer Institute, Boston
Study of REM-422 in Patients With AML or Higher Risk MDS
Vključevanje udeležencevFaza 1
- Massachusetts General Hospital, Boston
Študije za Akutna mieločna levkemija v drugih mestih
- Houston, TX85 študij
- New York City, NY51 študij
- Baldwin Park, CA40 študij
- Seattle, WA40 študij
- Columbus, OH35 študij
- Philadelphia, PA34 študij
- Durham, NC33 študij
- Atlanta, GA30 študij
- Tampa, FL29 študij
- Chicago, IL26 študij
- Portland, OR25 študij
- Miami, FL24 študij
Druge študije v Boston
- Rak dojke111 študij
- Nemalicelični pljučni rak90 študij
- Rak (vse vrste)86 študij
- Kolorektalni rak63 študij
- Metastatski rak63 študij
- Rak pljuč62 študij
- Rak jajčnikov61 študij
- Rak prostate59 študij
- Depresija52 študij
- Rak endometrija50 študij
- Srčno popuščanje44 študij
- Rak trebušne slinavke43 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.